Dayspring Pharma Reports Positive Phase II Results for CG2001 in Male Pattern Hair Loss

New Clinical Data Shows Promising Hair Growth Results

Dayspring Pharma has announced positive topline results from its Phase II clinical trial evaluating CG2001, an investigational topical treatment for androgenetic alopecia (AGA), commonly known as male pattern hair loss.

The study achieved its primary endpoint and demonstrated meaningful improvements in hair growth, particularly in patients using the twice-daily treatment regimen. The results also showed a favorable safety and tolerability profile, supporting the continued development of the therapy.

As hair loss continues to affect millions of men worldwide, these findings offer encouraging news for patients looking for more effective treatment options.

Understanding Androgenetic Alopecia

Androgenetic alopecia is the most common form of hair loss in men. It typically causes gradual thinning of hair, especially around the crown and hairline.

While several treatments are currently available, many patients are still looking for solutions that provide stronger results with minimal side effects. Because of this, male pattern hair loss remains an area with significant unmet medical need.

Dayspring Pharma believes CG2001 could become a new treatment option that addresses some of these challenges.

What Is CG2001?

CG2001 is a topical foam formulation that combines two well-known hair loss treatments:

• Minoxidil

• Finasteride

Both medicines are widely used as first-line therapies for androgenetic alopecia.

Minoxidil helps stimulate hair growth and improve blood flow around hair follicles. Finasteride works by reducing levels of dihydrotestosterone (DHT), a hormone strongly linked to hair follicle shrinkage and hair loss.

The goal of CG2001 is to combine the benefits of both treatments into a single topical product.

According to Dayspring Pharma, the formulation has been specifically designed to improve delivery of the active ingredients directly to the hair follicles while minimizing systemic exposure that can sometimes occur with oral finasteride.

How the Phase II Study Was Designed

The Phase II trial evaluated several dosing regimens of CG2001 in men with androgenetic alopecia.

The treatment groups included:

• CG2001 containing 5% Minoxidil and 0.075% Finasteride once daily

• CG2001 containing 5% Minoxidil and 0.1% Finasteride once daily

• CG2001 containing 5% Minoxidil and 0.075% Finasteride twice daily

• Placebo control group

Researchers evaluated the effectiveness of treatment over a 24-week period.

The primary measurement used in the study was Target Area Hair Count (TAHC), a commonly used indicator of hair growth that measures the number of hairs within a specific scalp area.

Study Meets Primary Endpoint

The study successfully met its primary endpoint.

At Week 24, participants receiving CG2001 containing 5% Minoxidil and 0.075% Finasteride twice daily showed a statistically significant improvement in Target Area Hair Count compared with the placebo group.

This result demonstrates that the treatment produced meaningful hair growth during the study period.

Significant Increase in Hair Count

One of the most notable findings from the trial was the improvement in hair count among patients using the twice-daily regimen.

At Week 24:

• The CG2001 twice-daily group showed an average increase of 28.17 hairs per square centimeter from baseline.

• The placebo group showed an average increase of 7.68 hairs per square centimeter.

The difference was statistically significant, with a p-value of 0.006.

These results suggest that the treatment provided a substantially greater improvement in hair density compared to placebo.

Hair Growth Improved Over Time

Researchers also observed a consistent trend of increasing hair growth throughout the study.

In the group receiving CG2001 with 5% Minoxidil and 0.075% Finasteride twice daily, improvements in Target Area Hair Count were seen at multiple evaluation points, including:

• Week 6

• Week 12

• Week 18

• Week 24

This steady upward trend suggests that continued use of the treatment may lead to ongoing improvements in hair growth over time.

Positive Feedback from Participants

In addition to objective hair count measurements, researchers also assessed how participants viewed their own treatment results.

Patients receiving the twice-daily CG2001 regimen showed a positive trend in self-assessments throughout the study.

While detailed patient-reported outcome data have not yet been fully disclosed, the findings suggest that participants noticed visible improvements in their hair condition during treatment.

Encouraging Safety Results

Safety is an important consideration for any hair loss treatment, especially when finasteride is involved.

According to Dayspring Pharma, CG2001 was generally well tolerated across all treatment groups.

Key safety findings included:

• No sex-related adverse events were identified

• All reported adverse events were mild to moderate in severity

• The treatment demonstrated favorable overall tolerability

These results support the company's goal of developing a topical formulation that maximizes local benefits while minimizing unwanted systemic effects.

Why This Matters

Although treatments for androgenetic alopecia already exist, many patients remain dissatisfied with available options due to limited effectiveness, side effects, or treatment convenience.

By combining minoxidil and finasteride into a specifically engineered topical foam, CG2001 aims to provide stronger hair growth benefits while reducing concerns associated with oral treatment approaches.

According to Dayspring Pharma CEO Baohui Yu, the company is encouraged by the study findings and believes the results support CG2001's potential as a differentiated treatment option for male pattern hair loss.

What Happens Next?

Following the positive Phase II results, Dayspring Pharma is now working with regulatory authorities to determine the next stage of clinical development.

Future studies will likely focus on confirming the treatment's effectiveness and safety in larger patient populations.

These additional trials will be important in determining whether CG2001 can move toward regulatory approval and eventual commercialization.

Looking Ahead

The positive Phase II results represent an important milestone for Dayspring Pharma and for the ongoing development of CG2001.

The treatment successfully met its primary endpoint, delivered significant improvements in hair count, demonstrated positive trends in patient assessments, and maintained a favorable safety profile.

As the company prepares for the next phase of development, CG2001 may emerge as a promising new option for men living with androgenetic alopecia who are seeking effective and convenient treatment solutions.

With further clinical validation, this combination therapy could play an important role in the future management of male pattern hair loss.